GlassScriptPhysician profile
Daniel Barton Mosher
NPI 1235516071
$9,292.20
in general payments reported to CMS, 2019-2025
41 companies · $1,417 in 2025
The $1,417 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $507 · 2020: $1,319 · 2021: $1,998 · 2022: $1,752 · 2023: $780 · 2024: $1,519 · 2025: $1,417.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,691 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,691.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $24.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,278.66 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,060.21 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $1,016.02 | 2019-2025 | |
| Novo Nordisk INC | $841.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $810.54 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.33 | 2019-2025 | Jardiance, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $409.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $371.77 | 2019-2025 | Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $325.76 | 2020-2024 | Spravato |
| Amgen INC. | $310.16 | 2019-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $201.62 | 2022 | |
| Amarin Pharma, INC. | $200.67 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $162.98 | 2021-2025 | Rexulti |
| Corcept Therapeutics | $162.67 | 2025 | Korlym |
| Biohaven Pharmaceuticals, INC. | $141.90 | 2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mosher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.